CSE: HUGE NASDAQ: HUGE FRA: 0K9A
CSE: HUGE NASDAQ: HUGE FRA: 0K9A

About Us

FSD Pharma is a specialty biotech pharmaceutical R&D company. FSD Pharma BioSciences, a wholly-owned subsidiary, is focused on developing over time multiple applications of the company’s lead compound FSD201, ultra-micronized palmitoylethanolamide (PEA), by down-regulating the cytokines to effectuate an anti-inflammatory response.

READ MORE

Our Mission

We are a science driven company focused on the research and development of FDA approved pharmaceuticals addressing acute and chronic medical conditions.

News

June 22, 2020

FSD Pharma Reports Favorable Topline Results from Phase 1 First-in-Human Safety and Tolerability Study of Ultramicronized PEA

Learn More »
June 9, 2020

FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors

Learn More »
June 4, 2020

FSD Pharma Inc. Announces C$10.125 Million Private Placement

Learn More »
MORE NEWS & MEDIA